We have located links that may give you full text access.
Comment
Journal Article
How effective is intravenous immunoglobulin for the treatment of relapsing-remitting multiple sclerosis?
Nature Clinical Practice. Neurology 2008 November
Intravenous immunoglobulin (IVIg) has been extensively used to treat humoral immunodeficiency states and various immune-mediated conditions. Several studies indicate that the benefits of IVIg with respect to relapses and MRI lesion activity compare favorably with those of interferon beta and glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndromes. Fazekas et al. recently reported the results of a multinational, randomized, double-blind, placebo-controlled phase II trial of a new preparation of IVIg in 127 participants with RRMS. No significant benefit was demonstrated for IVIg compared with placebo for the primary end point (proportion of relapse-free participants), the main secondary end point (cumulative number of unique newly active brain MRI lesions), or a number of clinical and MRI tertiary end points. Neither the previous positive studies nor the negative results reported by Fazekas et al. can be considered to be definitive, and the utility of IVIg in RRMS remains uncertain at present.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app